Repligen Corp
€98.85
EUR
Last updated on --.
24h volume24.00
24h highest99.0926 EUR
24h lowest98.9123 EUR
24h Price movement-0.07%
RGEN recent prices
24 Hours
-0.07%-€0.068704
30 days
-2.69%-€2.731
60 days
+4.56%+€4.311
90 days
-13.87%-€15.93
Key data
Previous close98.9252 EUR
Market cap5.41B EUR
Volume24.00
P/E ratio122.630000
Dividend yield (TTM)0.00%
Dividend amount--
Next ex-dividend date--
Next payment date--
EPS diluted (TTM)0.78151 EUR
Net income (FY)44.14M EUR
Revenue (FY)655.56M EUR
Last report dateMay 6, 2026
About Repligen Corp
HeadquartersWALTHAM
Employees (FY)2.00K
Revenue per employee (FY)327.78K EUR
Net income per employee (FY)22.07K EUR
Listed onNasdaq
RGEN conversion tables
 |  |
|---|---|
| 0.5 RGEN | 49.42 EUR |
| 1 RGEN | 98.85 EUR |
| 5 RGEN | 494.28 EUR |
| 10 RGEN | 988.56 EUR |
| |
|---|---|
| 0.5 EUR | 0.0050578 RGEN |
| 1 EUR | 0.010116 RGEN |
| 5 EUR | 0.050578 RGEN |
| 10 EUR | 0.10116 RGEN |
More to explore
Trending stock
Trending stock PERP
Trending stock token
FAQ
RGEN is trading at €98.85, -0.07% over the last 24 hours. Track live moves on the price chart at the top of this page.
The RGEN stock forecast depends on a mix of factors — broader market conditions, sector trends, and company-specific drivers like earnings, product cycles, and macro signals. RGEN is currently trading at €98.85, -0.07% over the last 24 hours, which reflects how the market is pricing these factors today. For a longer-term outlook on RGEN price action, review the 30-day, 60-day, and 90-day performance shown above, monitor momentum across the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector, and watch overall market sentiment. Stock forecasts and price predictions are inherently uncertain — always DYOR.
P/E ratio (Price-to-Earnings, trailing twelve months) measures how much investors pay per dollar of earnings over the last 12 months. RGEN's P/E ratio is currently 122.630000 — calculated by dividing its share price by its trailing 12-month earnings per share (EPS). A higher P/E suggests investors expect stronger future growth from RGEN; a lower P/E may indicate the stock is undervalued or that the market is pricing in a weaker outlook. P/E ratios are most useful when compared against RGEN's historical range and other companies in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector.
Repligen Corp's market cap is currently 5.41B EUR. Market cap is calculated as stock price × total shares outstanding.
Disclaimer
The social content on this page ("Content"), including but not limited to tweets and statistics provided by LunarCrush, is sourced from third parties and provided "as is" for informational purposes only. OKX does not guarantee the quality or accuracy of the Content, and the Content does not represent the views of OKX. It is not intended to provide (i) investment advice or recommendation; (ii) an offer or solicitation to buy, sell or hold digital assets; or (iii) financial, accounting, legal or tax advice. Digital assets, including stablecoins and NFTs, involve a high degree of risk and can fluctuate greatly. The price and performance of the digital assets are not guaranteed and may change without notice.
OKX does not provide investment or asset recommendations. You should carefully consider whether trading or holding digital assets is suitable for you in light of your financial condition. Please consult your legal/tax/investment professional for questions about your specific circumstances. For further details, please refer to our Terms of Use and Risk Warning.
OKX does not provide investment or asset recommendations. You should carefully consider whether trading or holding digital assets is suitable for you in light of your financial condition. Please consult your legal/tax/investment professional for questions about your specific circumstances. For further details, please refer to our Terms of Use and Risk Warning.
24h volume24.00
24h highest99.0926 EUR
24h lowest98.9123 EUR
24h Price movement-0.07%
Start trade with RGEN Perpetual
Sign up to trade